Canaccord Genuity Maintains Hold on Caris Life Sciences, Lowers Price Target to $22

Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and lowers the price target from $30 to $22.